Sandra Abi Fadel1, Marc von Reppert1,2, Eve Kazarian1, E Zeynep Erson Omay3, Asher Marks4, Nicolas Linder5, Karl-Titus Hoffmann2, Armine Darbinyan6, Anita Huttner6, Mariam S Aboian7. 1. Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. 2. Department of Neuroradiology, Leipzig University Hospital, Leipzig, Germany. 3. Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA. 4. Department of Pediatric Hematology/Oncology, Yale School of Medicine, New Haven, CT, USA. 5. Department of Diagnostic and Interventional Radiology, Leipzig University Hospital, Leipzig, Germany. 6. Department of Pathology, Yale School of Medicine, New Haven, CT, USA. 7. Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA. mariam.aboian@yale.edu.
Abstract
PURPOSE: Pilomyxoid astrocytomas (PMA) are pediatric brain tumors predominantly located in the suprasellar region, third ventricle and posterior fossa, which are considered to be more clinically aggressive than pilocytic astrocytomas (PA). Another entity, intermediate pilomyxoid tumors (IPT), exists within the spectrum of pilocytic/pilomyxoid astrocytomas. The 2021 WHO CNS classification refrained from assigning grade 1 or 2 status to PMA, thereby reflecting the need to further elucidate their clinical and imaging characteristics. METHODS: We included a total of 15 patients with PMA, IPT and suprasellar PA. We retrospectively evaluated immunohistochemistry, imaging findings and diffusion characteristics within these tumors as well as whole exome sequencing for three of the cases. RESULTS: 87% of the tumors were supratentorial with 11 cases suprasellar in location, 1 case located in the frontal white matter and 1 in the hippocampus. 6 cases demonstrated intraventricular extension. ADC values were higher in PMA and IPT than PA. 3 cases demonstrated KIAA1549-BRAF-fusion, 2 had BRAF[Formula: see text]-mutation and 6 were BRAF-wildtype. All cases had recurrence/progression on follow-up. CONCLUSION: PMA and IPT do not demonstrate aggressive imaging characteristics in respect to their diffusion imaging with ADC values being higher than PA. Lack of BRAF-alteration in PMA corresponded to atypical location of tumors with atypical driver mutations and mechanisms.
PURPOSE: Pilomyxoid astrocytomas (PMA) are pediatric brain tumors predominantly located in the suprasellar region, third ventricle and posterior fossa, which are considered to be more clinically aggressive than pilocytic astrocytomas (PA). Another entity, intermediate pilomyxoid tumors (IPT), exists within the spectrum of pilocytic/pilomyxoid astrocytomas. The 2021 WHO CNS classification refrained from assigning grade 1 or 2 status to PMA, thereby reflecting the need to further elucidate their clinical and imaging characteristics. METHODS: We included a total of 15 patients with PMA, IPT and suprasellar PA. We retrospectively evaluated immunohistochemistry, imaging findings and diffusion characteristics within these tumors as well as whole exome sequencing for three of the cases. RESULTS: 87% of the tumors were supratentorial with 11 cases suprasellar in location, 1 case located in the frontal white matter and 1 in the hippocampus. 6 cases demonstrated intraventricular extension. ADC values were higher in PMA and IPT than PA. 3 cases demonstrated KIAA1549-BRAF-fusion, 2 had BRAF[Formula: see text]-mutation and 6 were BRAF-wildtype. All cases had recurrence/progression on follow-up. CONCLUSION: PMA and IPT do not demonstrate aggressive imaging characteristics in respect to their diffusion imaging with ADC values being higher than PA. Lack of BRAF-alteration in PMA corresponded to atypical location of tumors with atypical driver mutations and mechanisms.
Authors: Jonathan A Forbes; Bret C Mobley; Thomas M O'Lynnger; Calvin M Cooper; Mahan Ghiassi; Rimal Hanif; Matthew M Pearson Journal: J Neurosurg Pediatr Date: 2011-07 Impact factor: 2.375
Authors: Michael W Johnson; Charles G Eberhart; Arie Perry; Tarik Tihan; Kenneth J Cohen; Marc K Rosenblum; Soroush Rais-Bahrami; Patricia Goldthwaite; Peter C Burger Journal: Am J Surg Pathol Date: 2010-12 Impact factor: 6.394
Authors: T Tihan; P G Fisher; J L Kepner; C Godfraind; R D McComb; P T Goldthwaite; P C Burger Journal: J Neuropathol Exp Neurol Date: 1999-10 Impact factor: 3.685
Authors: Ricardo J Komotar; Brad E Zacharia; Michael E Sughrue; J Mocco; Benjamin S Carson; Tarik Tihan; Marc L Otten; Peter C Burger; James H Garvin; Alexander G Khandji; Richard C E Anderson Journal: Neurol Res Date: 2008-07-25 Impact factor: 2.448
Authors: D Bhargava; P Sinha; P Chumas; Y Al-Tamimi; A Shivane; A Chakrabarty; S Surash; F Novegno; D Crimmins; A K Tyagi Journal: Br J Neurosurg Date: 2013-01-03 Impact factor: 1.596
Authors: Christoph Burkhard; Pier-Luigi Di Patre; Danielle Schüler; Georges Schüler; M Gazi Yaşargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki Journal: J Neurosurg Date: 2003-06 Impact factor: 5.115